{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:41:43Z","timestamp":1790710903672,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41375-025-02543-4","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:11:17Z","timestamp":1741158677000},"page":"779-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-4776","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ampatzidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-3115","authenticated-orcid":false,"given":"Nirmalya Roy","family":"Moulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-3327","authenticated-orcid":false,"given":"Sanjay","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Elhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-0360","authenticated-orcid":false,"given":"Mahmoud","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-5123","authenticated-orcid":false,"given":"Herbert","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-8832","authenticated-orcid":false,"given":"Haruko","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-2607","authenticated-orcid":false,"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Karow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6392-1590","authenticated-orcid":false,"given":"Roula","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Luesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dworzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sembill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-539X","authenticated-orcid":false,"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-6438","authenticated-orcid":false,"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Versluys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Athale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-054X","authenticated-orcid":false,"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-1676","authenticated-orcid":false,"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-8838","authenticated-orcid":false,"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2543_CR1","unstructured":"Millot F, Suttorp M. Chronic myeloid Leukemia in children. In: Alaggio R, Chan JKC, Hasle H, editors. Haematolymphoid disorders\u2014WHO classification book on paediatric tumours. 5th ed. Lyon: International Agency for Research on Cancer (IARC); 2023. p. 4\u20137."},{"key":"2543_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cancers13040798","volume":"13","author":"M Suttorp","year":"2021","unstructured":"Suttorp M, Millot F, Sembill S, Deutsch H, Metzler M. Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers. 2021;13:798.","journal-title":"Cancers"},{"key":"2543_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11899-022-00673-5","volume":"17","author":"M Ford","year":"2022","unstructured":"Ford M, Mauro M, Aftandilian C, Sakamoto KM, Hijiya N. Management of chronic myeloid leukemia in children and young adults. Curr Hematol Malig Rep. 2022;17:121\u20136.","journal-title":"Curr Hematol Malig Rep"},{"key":"2543_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjh.12977","volume":"167","author":"J de la Fuente","year":"2014","unstructured":"de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, et al. International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33\u201347.","journal-title":"Br J Haematol"},{"key":"2543_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27827","volume":"66","author":"U Athale","year":"2019","unstructured":"Athale U, Hijiya N, Patterson BC, Bergsagel J, Andolina JR, Bittencourt H, et al. Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children\u2019s Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66:e27827.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392\u20139.","journal-title":"Blood"},{"key":"2543_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41375-023-01822-2","volume":"37","author":"S Sembill","year":"2023","unstructured":"Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023;37:505\u201317.","journal-title":"Leukemia"},{"key":"2543_CR8","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood.2019000069","volume":"134","author":"N Hijiya","year":"2019","unstructured":"Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019;134:2036\u201345.","journal-title":"Blood"},{"key":"2543_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1200\/JCO.23.00897","volume":"42","author":"E Brivio","year":"2023","unstructured":"Brivio E, Pennesi E, Willemse ME, Huitema ADR, Jiang Y, van Tinteren HDR, et al. Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921. J Clin Oncol. 2023;42:821\u201331.","journal-title":"J Clin Oncol"},{"key":"2543_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2023-173810","volume":"142","author":"F Millot","year":"2023","unstructured":"Millot F, De Keizer J, Metzler M, Suttorp M, Sedlacek P, Luesink M, et al. Is the Eutos Long Term Survival (ELTS) score a useful marker to predict outcome in children with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP)? The experience of the International Registry of Childhood CML ; abstracts from the 2023 Annual Scientific Meeting of the American Society of Hematology (ASH). Blood. 2023;142:448.","journal-title":"Blood"},{"key":"2543_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-022-05024-1","volume":"102","author":"F Delehaye","year":"2023","unstructured":"Delehaye F, Rouger J, Brossier D, Suttorp M, G\u00fcne\u015f AM, Sedlacek P, et al. Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course. Ann Hematol. 2023;102:563\u201370.","journal-title":"Ann Hematol"},{"key":"2543_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.16241","volume":"188","author":"R Kn\u00f6fler","year":"2020","unstructured":"Kn\u00f6fler R, Lange BS, Paul F, Tiebel O, Suttorp M. Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children. Br J Haematol. 2020;188:701\u20136.","journal-title":"Br J Haematol"},{"key":"2543_CR13","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","volume":"29","author":"F Millot","year":"2011","unstructured":"Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011;29:2827\u201332.","journal-title":"J Clin Oncol"},{"key":"2543_CR14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","volume":"32","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Schulze P, Glauche I, G\u00f6hring G, von Neuhoff N, Metzler M, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018;32:1657\u201369.","journal-title":"Leukemia"},{"key":"2543_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumors: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2543_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2543_CR17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2543_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.23.01689","volume":"42","author":"E Berman","year":"2024","unstructured":"Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, et al. CML and the WHO: Why? J Clin Oncol. 2024;42:984\u20136.","journal-title":"J Clin Oncol"},{"key":"2543_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2019.03.020","volume":"115","author":"F Millot","year":"2019","unstructured":"Millot F, Maledon N, Guilhot J, G\u00fcne\u015f AM, Kalwak K, Suttorp M. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer. 2019;115:17\u201323.","journal-title":"Eur J Cancer"},{"key":"2543_CR20","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1002\/cncr.30767","volume":"123","author":"F Millot","year":"2017","unstructured":"Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T, et al. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer. 2017;123:3609\u201316.","journal-title":"Cancer"},{"key":"2543_CR21","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/cancers14071712","volume":"14","author":"A Karow","year":"2022","unstructured":"Karow A, G\u00f6hring G, Sembill S, Lutterloh F, Neuhaus F, Callies S, et al. The cytogenetic landscape of pediatric chronic myeloid leukemia diagnosed in chronic phase. Cancers. 2022;14:1712.","journal-title":"Cancers"},{"key":"2543_CR22","first-page":"942","volume":"109","author":"YL Behrens","year":"2024","unstructured":"Behrens YL, Gaschler L, Nienhold R, Reinkens T, Schirmer E, Kn\u00f6\u00df S, et al. Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia. Haematologica. 2024;109:942\u20137.","journal-title":"Haematologica"},{"key":"2543_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"2543_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffman V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"2543_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia"},{"key":"2543_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","volume":"94","author":"DG Salas","year":"2015","unstructured":"Salas DG, Glauche I, Tauer JT, Thiede C, Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients. Ann Hematol. 2015;94:1363\u201371.","journal-title":"Ann Hematol"},{"key":"2543_CR27","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","volume":"102","author":"F Millot","year":"2017","unstructured":"Millot F, Guilhot J, Suttorp M, Meral G\u00fcnes A, Sedlacek P, De Bont E, et al. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Haematologica. 2017;102:1704\u201308.","journal-title":"Haematologica"},{"key":"2543_CR28","unstructured":"Fischer MJ, Rheingold SR. Oncologic emergencies. In: Pizzo PA, Poplack DG, editors. Principles and practices of pediatric oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2011. p. 1125\u201351."},{"key":"2543_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/pbc.25803","volume":"63","author":"H Kurosawa","year":"2016","unstructured":"Kurosawa H, Tanizawa A, Tono C, Watanabe A, Shima H, Ito M, et al. Leukostasis in children and adolescents with chronic myeloid leukemia: Japanese Pediatric Leukemia\/Lymphoma Study Group. Pediatr Blood Cancer. 2016;63:406\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1542\/peds.2004-2473","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140\u20133.","journal-title":"Pediatrics"},{"key":"2543_CR31","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00277-021-04544-6","volume":"100","author":"X Dou","year":"2021","unstructured":"Dou X, Zheng F, Zhang L, Jin J, Zhang Y, Liu B, et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol. 2021;100:2215\u201328.","journal-title":"Ann Hematol"},{"key":"2543_CR32","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/bjh.19251","volume":"204","author":"N Roy Moulik","year":"2024","unstructured":"Roy Moulik N, Keerthivasagam S, Pandey A, Agiwale J, Hegde K, Chatterjee G, et al. Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era\u2014two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort. Br J Haematol. 2024;204:1249\u201361.","journal-title":"Br J Haematol"},{"key":"2543_CR33","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.3390\/jcm12144776","volume":"12","author":"M Suttorp","year":"2023","unstructured":"Suttorp M, Sembill S, Kalwak K, Metzler M, Millot F. Priapism at diagnosis of pediatric chronic myeloid leukemia: data derived from a large cohort of children and teenagers and a narrative review on priapism management. J Clin Med. 2023;12:4776.","journal-title":"J Clin Med"},{"key":"2543_CR34","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.2147\/IJGM.S321787","volume":"14","author":"D Zhang","year":"2021","unstructured":"Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and hyperleukocytosis, past and future. Int J Gen Med. 2021;14:3457\u201367.","journal-title":"Int J Gen Med"},{"key":"2543_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3109\/08880018.2013.831961","volume":"31","author":"S Kumar","year":"2014","unstructured":"Kumar S, Bansal D, Prakash M, Sharma P. Avascular necrosis of femoral head as the initial manifestation of CML. Pediatr Hematol Oncol. 2014;31:568\u201373.","journal-title":"Pediatr Hematol Oncol"},{"key":"2543_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ucl.2021.07.003","volume":"48","author":"C Ericson","year":"2021","unstructured":"Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48:565\u201376.","journal-title":"Urol Clin North Am"},{"key":"2543_CR37","doi-asserted-by":"crossref","unstructured":"Roy Moulik N, Harriss-Buchan A, Saglio G, Evans N, Suttorp M. Cases of patients treated in countries with limited resources and discussed by experts of the International CML Foundation (iCMLf); Case No. 1: a boy presenting with priapism and loss of vision. Case Rep Oncol Med. 2024:5534445.","DOI":"10.1155\/2024\/5534445"},{"key":"2543_CR38","doi-asserted-by":"publisher","first-page":"e16984","DOI":"10.1097\/MD.0000000000016984","volume":"98","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang L, Xi Y, Li Z. Bleeding with negative coagulation screening test as initial presentation of chronic myelogenous leukemia managed by fresh frozen plasma: a case report. Medicine. 2019;98:e16984.","journal-title":"Medicine"},{"key":"2543_CR39","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1097\/MPH.0000000000000204","volume":"36","author":"T Aksu","year":"2014","unstructured":"Aksu T, Erdem AY, Fettah A, Ka\u00e7ar D, Avci Z, Yarali N, et al. Massive splenic infarction and portal vein thrombosis in children with chronic myeloid leukemia. J Pediatr Hematol Oncol. 2014;36:e471\u20132.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2543_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00431-012-1675-y","volume":"171","author":"D Drummond","year":"2012","unstructured":"Drummond D, Lenoir M, Petit AY. Splenic infarction in a child revealing chronic myeloid leukemia. Eur J Pediatr. 2012;171:1141\u20132.","journal-title":"Eur J Pediatr"},{"key":"2543_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","volume":"170","author":"F Giona","year":"2015","unstructured":"Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015;170:398\u2013407.","journal-title":"Br J Haematol"},{"key":"2543_CR42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/pbc.25120","volume":"61","author":"K Sadak","year":"2014","unstructured":"Sadak K, Fultz K, Mendizaba A, Reaman G, Garcia-Gonzalez P, Levine PH. International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted Nations. Pediatr Blood Cancer. 2014;61:1774\u201378.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27431","volume":"65","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Metzler M, Millot F, Shimada H, Bansal D, Meral G\u00fcnes A, et al. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. Pediatr Blood Cancer. 2018;65:e27431.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","volume":"36","author":"L Gore","year":"2018","unstructured":"Gore L, Kearns PR, de Martino ML, Lee De Souza CA, Bertrand Y, Hijiya N, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36:1330\u20138.","journal-title":"J Clin Oncol"},{"key":"2543_CR45","unstructured":"Pennesi E, Brivio E, Willemse ME, de Boer EC, Jiang, Y, Van der Velden V, et al. One year analysis of growth data in newly-diagnosed pediatric patients with chronic myeloid leukemia treated with Bosutinib: results from trial ITCC-054\/COG-AAML1921 (Abstract release date: 05\/14\/24) EHA Library. Pennesi E. 06\/13\/2024; 420781; P717."},{"key":"2543_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"H Hochhaus","year":"2024","unstructured":"Hochhaus H, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.","journal-title":"N Engl J Med"},{"key":"2543_CR47","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.1200\/JCO.2024.42.16_suppl.6562","volume":"42","author":"N Hijiya","year":"2024","unstructured":"Hijiya N, Shimada H, Kapoor S, Hoch M, Cardoso A, Dhamal V, et al. Pharmacokinetics and safety of asciminib (ASC) in pediatric patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): interim results from the ASC4KIDS study (Abstract). J Clin Oncol. 2024;42:6562.","journal-title":"J Clin Oncol"},{"key":"2543_CR48","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","volume":"140","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014;140:1965\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2543_CR49","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"1","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;1:2401\u20139.","journal-title":"Leukemia"},{"key":"2543_CR50","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","volume":"124","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014;124:2408\u201310.","journal-title":"Blood"},{"key":"2543_CR51","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/pharmaceutics14081676","volume":"14","author":"H Johnson-Ansah","year":"2022","unstructured":"Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al. Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia. Pharmaceutics. 2022;14:1676.","journal-title":"Pharmaceutics"},{"key":"2543_CR52","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496\u20139.","journal-title":"Blood"},{"key":"2543_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265278","volume":"17","author":"DN Shelton","year":"2022","unstructured":"Shelton DN, Bhagavatula P, Sepuvelda N, Beppu L, Gandhi S, Qin D, et al. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia. PLoS ONE. 2022;17. e0265278.","journal-title":"PLoS ONE"},{"key":"2543_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/10428194.2020.1855340","volume":"62","author":"EJ Chow","year":"2021","unstructured":"Chow EJ, Doody DR, Wilkes JJ, Becker LK, Chennupati S, Morin PE, et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021;62:1203\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2543_CR55","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cpt.1808","volume":"108","author":"JM Janssen","year":"2020","unstructured":"Janssen JM, Dorlo TPC, Steeghs N, Beijnen JH, Hanff LM, Van Eijkelenburg NKA, et al. Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin Pharmacol Ther. 2020;108:494\u2013505.","journal-title":"Clin Pharmacol Ther"},{"key":"2543_CR56","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","volume":"31","author":"CM Zwaan","year":"2013","unstructured":"Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31:2460\u20138.","journal-title":"J Clin Oncol"},{"key":"2543_CR57","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","volume":"26","author":"N Hijiya","year":"2020","unstructured":"Hijiya N, Zwaan CM, Rizzari C, Fo\u00e0 R, Abbink F, Lancaster D, et al. Pharmacokinetics of nilotinib in pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:812\u201320.","journal-title":"Clin Cancer Res"},{"key":"2543_CR58","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","volume":"5","author":"N Hijiya","year":"2021","unstructured":"Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, et al. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv. 2021;5:2925\u201334.","journal-title":"Blood Adv"},{"key":"2543_CR59","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1182\/bloodadvances.2023010122","volume":"7","author":"N Hijiya","year":"2023","unstructured":"Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, et al. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Adv. 2023;7:7279\u201389.","journal-title":"Blood Adv"},{"key":"2543_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pbc.23031","volume":"57","author":"MA Champagne","year":"2011","unstructured":"Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2011;57:56\u201362.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR61","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers15153862","volume":"15","author":"JW Yoo","year":"2023","unstructured":"Yoo JW, Jo S, Ahn MB, Kim S, Lee JW, Kim M, et al. Front-line tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: a study on efficacy and safety. Cancers. 2023;15:3862.","journal-title":"Cancers"},{"key":"2543_CR62","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","volume":"29","author":"R Aplenc","year":"2011","unstructured":"Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children\u2019s oncology group phase I consortium. J Clin Oncol. 2011;29:839\u201344.","journal-title":"J Clin Oncol"},{"key":"2543_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29786","volume":"69","author":"EE Dong","year":"2022","unstructured":"Dong EE, Bruno MA, Kim JJ, Bernhardt MB, Brown AL, Gramatges MM. Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2022;69:e29786.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16338","volume":"189","author":"J Rossoff","year":"2020","unstructured":"Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, et al. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020;189:363\u20138.","journal-title":"Br J Haematol"},{"key":"2543_CR65","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.05.020","volume":"136","author":"F Millot","year":"2020","unstructured":"Millot F, Suttorp M, Versluys AB, Kalwak K, Nelken B, Ducassou S, et al. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. Eur J Cancer. 2020;136:107\u201312.","journal-title":"Eur J Cancer"},{"key":"2543_CR66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12185-022-03329-5","volume":"116","author":"Y Kodama","year":"2022","unstructured":"Kodama Y, Sato A, Kato K, Sakaguchi H, Kato M, Kawasaki H, et al. Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children\u2019s Cancer Group. Int J Hematol. 2022;116:131\u20138.","journal-title":"Int J Hematol"},{"key":"2543_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Sig Transduct Target Ther. 2023;8:262.","journal-title":"Sig Transduct Target Ther"},{"key":"2543_CR68","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","volume":"98","author":"F Giona","year":"2013","unstructured":"Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica. 2013;98:e25.","journal-title":"Haematologica"},{"key":"2543_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pbc.23389","volume":"59","author":"D Bansal","year":"2012","unstructured":"Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR70","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/blood.V124.21.522.522","volume":"124","author":"JT Tauer","year":"2014","unstructured":"Tauer JT, Nowasz C, Sedlacek P, de Bont ES, Aleinikova OV, Suttorp M. Impairment of longitudinal growth by tyrosine kinase inhibitor (TKI) treatment-data from a large pediatric cohort with chronic myeloid leukemia (CML). Blood. 2014;124:522.","journal-title":"Blood"},{"key":"2543_CR71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","volume":"159","author":"H Shima","year":"2011","unstructured":"Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676\u201381.","journal-title":"J Pediatr"},{"key":"2543_CR72","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","volume":"50","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50:3206\u201311.","journal-title":"Eur J Cancer"},{"key":"2543_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MPH.0000000000002660","volume":"45","author":"P Gupta","year":"2023","unstructured":"Gupta P, Banothu KK, Haldar P, Gupta AK, Meena JP. Effect of imatinib mesylate on growth in pediatric chronic myeloid leukemia: a systematic review and meta-analysis. J Pediatr Hematol Oncol. 2023;45:227\u201334.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2543_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.HS9.0000559876.36369.09","volume":"3","author":"BS Patterson","year":"2019","unstructured":"Patterson BS, Samis J, Gore L, Zwaan CM, Sacchi M, Sy O, et al. Growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase Abstract. HemaSphere. 2019;3:161\u20132.","journal-title":"HemaSphere"},{"key":"2543_CR75","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/pbc.24397","volume":"60","author":"KR Narayanan","year":"2013","unstructured":"Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis. Pediatr Blood Cancer. 2013;60:1148\u201353.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR76","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/08880018.2019.1689320","volume":"37","author":"R Walia","year":"2020","unstructured":"Walia R, Aggarwal A, Bhansali A, Aggarwal A, Varma N, Sachdeva N, et al. Acquired neuro-secretory defect in growth hormone secretion due to Imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia. Pediatr Hematol Oncol. 2020;37:99\u2013108.","journal-title":"Pediatr Hematol Oncol"},{"key":"2543_CR77","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","volume":"12","author":"X Chang","year":"2017","unstructured":"Chang X, Zhou L, Chen X, Xu B, Cheng Y, Sun S, et al. Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase. Target Oncol. 2017;12:827\u201332.","journal-title":"Target Oncol"},{"key":"2543_CR78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMc0707841","volume":"358","author":"C Christopoulos","year":"2008","unstructured":"Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358:1079\u201380.","journal-title":"N Engl J Med"},{"key":"2543_CR79","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","volume":"14","author":"A Pallera","year":"2016","unstructured":"Pallera A, Altman JK, Berman E, et al. NCCN guidelines insight\u2014chronic myeloid leukemia. J Natl Compr Canc Netw. 2016;14:1505\u201312.","journal-title":"J Natl Compr Canc Netw"},{"key":"2543_CR80","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505\u20138.","journal-title":"Blood"},{"key":"2543_CR81","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/pbc.26028","volume":"63","author":"J Samis","year":"2016","unstructured":"Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy In Children With Chronic Myelogenous Leukemia. Pediatr Blood Cancer. 2016;63:1332.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR82","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","volume":"8","author":"RR Ganta","year":"2016","unstructured":"Ganta RR, Nasaka S, Gundeti S. Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia\u2014chronic phase. Indian J Pediatr. 2016;8:1009\u201312.","journal-title":"Indian J Pediatr"},{"key":"2543_CR83","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/PPA.S269355","volume":"15","author":"BK Tan","year":"2021","unstructured":"Tan BK, Bee PC, Chua SS, Chen LC. Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review. Patient Prefer Adherence. 2021;15:2563\u201375.","journal-title":"Patient Prefer Adherence"},{"key":"2543_CR84","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","volume":"11","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Bornh\u00e4user M, Metzler M, Millot F, Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients. Expert Rev Clin Pharmacol. 2018;11:219\u201331.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2543_CR85","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/bjh.13103","volume":"168","author":"F Giona","year":"2015","unstructured":"Giona F, Saglio G, Moleti ML, Piciocchi A, Rea M, Nanni M, et al. Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. Br J Haematol. 2015;168:305\u20138.","journal-title":"Br J Haematol"},{"key":"2543_CR86","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3390\/cancers13164102","volume":"13","author":"F Millot","year":"2021","unstructured":"Millot F, Suttorp M, Ragot S, Leverger G, Dalle JH, Thomas C, et al. Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the International Registry of Childhood CML. Cancers. 2021;13:4102\u20139.","journal-title":"Cancers"},{"key":"2543_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29699","volume":"69","author":"H Shima","year":"2022","unstructured":"Shima H, Kada A, Tanizawa A, Sato I, Tono C, Ito M, et al. A Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 2022;69:e29699.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR88","doi-asserted-by":"crossref","unstructured":"Roy Moulik N, Keerthivasagam S, Chatterjee G, Agiwale J, Rane P, Dhamne C, et al. Treatment-free remissions in children with chronic myeloid leukemia (CML): a prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort. Am J Hematol. 2024;100:210\u20137.","DOI":"10.1002\/ajh.27528"},{"key":"2543_CR89","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","volume":"32","author":"F Millot","year":"2003","unstructured":"Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transpl. 2003;32:993\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2543_CR90","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","volume":"102","author":"K Cwynarski","year":"2003","unstructured":"Cwynarski K, Roberts IA, Iacobelli S, Van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224\u201331.","journal-title":"Blood"},{"key":"2543_CR91","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","volume":"16","author":"H Muramatsu","year":"2010","unstructured":"Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transpl. 2010;16:231\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2543_CR92","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0029-1239529","volume":"221","author":"M Suttorp","year":"2009","unstructured":"Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr. 2009;221:351\u20137.","journal-title":"Klin Padiatr"},{"key":"2543_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27368","volume":"65","author":"H Kurosawa","year":"2018","unstructured":"Kurosawa H, Tanizawa A, Muramatsu H, Tono C, Watanabe A, Shima H, et al. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: a report from the Japanese Pediatric Leukemia\/Lymphoma Study Group. Pediatr Blood Cancer. 2018;65:e27368.","journal-title":"Pediatr Blood Cancer"},{"key":"2543_CR94","first-page":"134","volume":"71","author":"H Kurosawa","year":"2024","unstructured":"Millot F, Duche J, G\u00fcnes AM, Kalwak K, Metzler M, Suttorp M et al. Hematopoietic stem cell allograft in children and adolescents with chronic myeloid leukemia in chronic phase: the experience of the International registry for childhood chronic myeloid leukemia (I-CML-Ped Study). Abstract from the 2024 Annual Scientific Meeting of the International Society of Pediatric Oncology (SIOP). Pediatric Blood Cancer. 2024;71:134.","journal-title":"Pediatric Blood Cancer"},{"key":"2543_CR95","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","volume":"22","author":"S Chaudhury","year":"2016","unstructured":"Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, et al. Outcomes of allogeneic hematopoietic cell transplantation in children and young adults with chronic myeloid leukemia: a CIBMTR cohort analysis. Biol Blood Marrow Transpl. 2016;22:1056\u201364.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2543_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13664","volume":"24","author":"HA Hafez","year":"2020","unstructured":"Hafez HA, Abdallah A, Hammad M, Hamdy N, Yassin D, Salem S, et al. Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: single-center experience. Pediatr Transpl. 2020;24:e13664.","journal-title":"Pediatr Transpl"},{"key":"2543_CR97","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jtct.2022.04.011","volume":"28","author":"H Shimada","year":"2022","unstructured":"Shimada H, Tanizawa A, Kondo T, Nagamura-Inoue T, Yasui M, Tojo A, et al. Prognostic factors for outcomes of allogeneic HSCT for children and adolescents\/young adults with CML in the TKI era. Transpl Cell Ther. 2022;28:376\u201389.","journal-title":"Transpl Cell Ther"},{"key":"2543_CR98","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/bjh.19535","volume":"205","author":"H Pichler","year":"2024","unstructured":"Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, et al. Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: a prospective multicentre trial of the I-BFM Study Group. Br J Haematol. 2024;205:268\u201379.","journal-title":"Br J Haematol"},{"key":"2543_CR99","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3109\/10428194.2015.1065981","volume":"57","author":"L Broglie","year":"2016","unstructured":"Broglie L, Hijiya N, Helenowski IB, Dilley K, Schneiderman J, Tse W, et al. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy. Leuk Lymphoma. 2016;57:949\u201352.","journal-title":"Leuk Lymphoma"},{"key":"2543_CR100","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","volume":"19","author":"C Cutler","year":"2001","unstructured":"Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685\u201391.","journal-title":"J Clin Oncol"},{"key":"2543_CR101","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.3390\/jcm10184056","volume":"10","author":"M Suttorp","year":"2021","unstructured":"Suttorp M, Carrion A, Hijiya N. Chronic myeloid leukemia in children: immune function and vaccinations. J Clin Med. 2021;10:4056.","journal-title":"J Clin Med"},{"key":"2543_CR102","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","volume":"122","author":"H de Lavallade","year":"2013","unstructured":"de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227\u201338.","journal-title":"Blood"},{"key":"2543_CR103","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fimmu.2020.00628","volume":"11","author":"C Bettoni da Cunha-Riehm","year":"2020","unstructured":"Bettoni da Cunha-Riehm C, Hildebrand V, Nathrath M, Metzler M, Suttorp M. Vaccination with live attenuated vaccines in four children with chronic myeloid leukemia while on imatinib treatment. Front Immunol. 2020;11:628.","journal-title":"Front Immunol"},{"key":"2543_CR104","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"2543_CR105","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37:2150\u201367.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02543-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:05:47Z","timestamp":1744218347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2543"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02543-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}